Stocks in play: Aeterna Zentaris Inc.
Announced the commencement of the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease). The preclinical development program is part of the recently executed Material Transfer Agreement (MTA) with The University of Queensland. Aeterna Zentaris Inc. shares T.AEZS are trading down $0.05 at $1.03.
Read: